Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective

Key TakeawaysAmerican depositary receipts of Novo Nordisk fell Tuesday while shares of Eli Lilly rose following results of a new study.A JAMA Internal Medicine study published Monday found that the active ingredient in Eli Lilly's Mounjaro and Zepbound caused greater weight loss than that of Novo Nordisk's Ozempic and Wegovy.The weight-loss drugs have substantially boosted both companies' earnings and stock prices over the last two years as demand has surged. The stock price of a pair of pharmaceutical comp ...